Latest filings (excl ownership)
S-8
Registration of securities for employees
14 Mar 24
S-3
Shelf registration
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
POSASR
Automatic shelf registration (post-effective amendment)
14 Mar 24
8-K
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023
14 Mar 24
10-K/A
2022 FY
Annual report (amended)
14 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Feb 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
Other Events
19 Dec 23
424B5
Prospectus supplement for primary offering
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
2 Nov 23
8-K/A
Departure of Directors or Certain Officers
17 Oct 23
8-K
Departure of Directors or Certain Officers
16 Oct 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
2 Aug 23
8-K
Other Events
21 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Other Events
7 Jun 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
3 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
8-K
Departure of Directors or Certain Officers
20 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
28 Feb 23
8-K
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Departure of Directors or Certain Officers
3 Jan 23
8-K
Other Events
29 Nov 22
S-3ASR
Automatic shelf registration
2 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
2 Nov 22
8-K
Other Events
6 Oct 22
8-K
Other Events
21 Sep 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
9 Aug 22
Latest ownership filings
144
Notice of proposed sale of securities
22 Apr 24
4
David D Chang
18 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Geoffrey M. Parker
6 Mar 24
SC 13G/A
Belldegrun Arie
14 Feb 24
SC 13G/A
Chang David D
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
TIMOTHY L. MOORE
31 Jan 24
4
Earl Martin Douglas
31 Jan 24
4
Geoffrey M. Parker
31 Jan 24
4
Arie Belldegrun
31 Jan 24
4
Zachary Roberts
31 Jan 24
4
David D Chang
31 Jan 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
Zachary Roberts
24 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
144
Notice of proposed sale of securities
22 Jan 24
4
DEBORAH M. MESSEMER
20 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
SC 13D/A
PFIZER INC
25 Oct 23
4
Geoffrey M. Parker
17 Oct 23
3
Geoffrey M. Parker
16 Oct 23
4
Earl Martin Douglas
17 Aug 23
3
Earl Martin Douglas
17 Aug 23
4
YINLIN JACK CHEN
14 Aug 23
3
YINLIN JACK CHEN
14 Aug 23
4
Stephen Mayo
9 Aug 23
144
Notice of proposed sale of securities
7 Aug 23
SC 13G
FMR LLC
10 Jul 23
144
Notice of proposed sale of securities
29 Jun 23
144
Notice of proposed sale of securities
20 Jun 23
4
DEBORAH M. MESSEMER
15 Jun 23
4
Elizabeth A. Barrett
15 Jun 23
4
VICKI L SATO
15 Jun 23
4
Franz B Humer
15 Jun 23
4
OWEN N. WITTE
15 Jun 23
4
Stephen Mayo
15 Jun 23
4
Joshua A Kazam
15 Jun 23
144
Notice of proposed sale of securities
12 Jun 23